Oxidative Medicine and Cellular Longevity

Oxidative Medicine and Cellular Longevity / 2019 / Article

Corrigendum | Open Access

Volume 2019 |Article ID 9601435 | https://doi.org/10.1155/2019/9601435

Stefania Gorini, Antonella De Angelis, Liberato Berrino, Natalia Malara, Giuseppe Rosano, Elisabetta Ferraro, "Corrigendum to “Chemotherapeutic Drugs and Mitochondrial Dysfunction: Focus on Doxorubicin, Trastuzumab, and Sunitinib”", Oxidative Medicine and Cellular Longevity, vol. 2019, Article ID 9601435, 1 page, 2019. https://doi.org/10.1155/2019/9601435

Corrigendum to “Chemotherapeutic Drugs and Mitochondrial Dysfunction: Focus on Doxorubicin, Trastuzumab, and Sunitinib”

Received21 Feb 2019
Accepted24 Feb 2019
Published26 Jun 2019

In the article titled “Chemotherapeutic Drugs and Mitochondrial Dysfunction: Focus on Doxorubicin, Trastuzumab, and Sunitinib” [1], the author Giuseppe Rosano should have been affiliated to the first and fourth affiliations. The corrected authors’ list is shown above.

References

  1. S. Gorini, A. De Angelis, L. Berrino, N. Malara, G. Rosano, and E. Ferraro, “Chemotherapeutic drugs and mitochondrial dysfunction: focus on doxorubicin, trastuzumab, and sunitinib,” Oxidative Medicine and Cellular Longevity, vol. 2018, Article ID 7582730, 15 pages, 2018. View at: Publisher Site | Google Scholar

Copyright © 2019 Stefania Gorini et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


More related articles

 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder
Views568
Downloads308
Citations

Related articles